ArticlePlastic and reconstructive surgery. Global open2025
Successful Treatment of Refractory Bilateral Leg Ulcers With an Adsorptive Blood-Purification Device.
Article in Plastic and reconstructive surgery. Global open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic limb-threatening ischemia (CLTI) is the most advanced stage of lower extremity artery disease. Patients with CLTI are often unsuitable for revascularization and thus have limited treatment options. In 2020, Japan approved Rheocarna for such cases. Rheocarna is an adsorptive blood-purification device that removes low-density lipoprotein cholesterol and fibrinogen. We presented the case of a 63-year-old man with chronic kidney disease and diabetes mellitus who presented with severe and progressing refractory ulcers. Angiography revealed severe arterial calcification, indicating CLTI. No targets for standard revascularization treatment were found. Together with wound care and hyperbaric oxygen, 20 Rheocarna treatment sessions improved circulation and ulcer healing, thus avoiding amputation. Thus, Rheocarna may be a promising therapy for CLTI patients who are ineligible for revascularization. Further studies are needed to validate its efficacy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.